Innovassynth Q1FY27: Margin rebound, order book visibility and capacity ramp
Frequently Asked Questions
The presentation is for Q1FY27, covering the quarter ended 30 June 2026 (dated 12 August 2026).
Revenue from operations was INR 5,599 lakhs (INR 55.99 crore), EBITDA was INR 1,497 lakhs (INR 14.97 crore), and PAT was INR 674 lakhs (INR 6.74 crore).
The open order book is stated at about INR 165 crore as of 30 June 2026.
Life Sciences about INR 84 crore, Specialty Chemicals about INR 15 crore, and CDMO about INR 66 crore.
The presentation lists three units: Life Sciences and Nucleosides, Specialty Chemicals, and Contract Research, Development and Manufacturing (CRDMO).
The presentation states about 90% of revenue is from global geographies, with key focus on USA and Europe.
Management states Life Sciences capacity expansion is on track and the planned addition is expected to double capacity, intended to support anticipated growth in CRDMO demand.
Did your stocks survive the war?
See what broke. See what stood.
Live Q1 Earnings Tracker